Abstract
We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m2) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.
Original language | English |
---|---|
Pages (from-to) | 1273-1274 |
Number of pages | 2 |
Journal | Haematologica |
Volume | 92 |
Issue number | 9 |
DOIs | |
Publication status | Published - Sep 2007 |
Keywords
- Acute promyelocytic leukemia
- Gentuzumab ozogamicin
- Molecular relapse
ASJC Scopus subject areas
- Hematology